Tear film stabilization and thickening

"Tear film stabilization and thickening" is not a specific molecule or receptor but rather describes the overall process by which the tear film on the ocular surface maintains its integrity, thickness, and stability. This process involves multiple components including membrane-associated mucins (such as MUC16), secretory mucins, aqueous fluid, lipids from meibomian glands, proteins like lactoferrin and lysozyme, as well as immunoglobulins. The stability of the tear film is crucial for protecting the ocular surface from desiccation and pathogens. Deficiencies in any component can lead to dry eye disease characterized by increased evaporation or decreased wettability. Therapeutic strategies for stabilizing or thickening the tear film include drugs that stimulate mucin secretion or enhance epithelial barrier function; examples are diquafosol sodium and rebamipide ophthalmic solutions[1][2][3]. Because "tear film stabilization and thickening" refers to a physiological outcome rather than an individual molecular target, it should not be classified as a canonical therapeutic target such as a receptor or enzyme.

Stimulation of mucin secretion (diquafosol sodium). Enhancement of mucin production and epithelial barrier function (rebamipide).